Trial Profile
A phase I clinical trial to determine the safety, long-acting duration, and sustainability of GX-H9
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jun 2016
Price :
$35
*
At a glance
- Drugs Eftansomatropin (Primary)
- Indications Dwarfism; Somatotropin deficiency
- Focus Adverse reactions; Pharmacokinetics
- 29 Feb 2016 New trial record